What is the ROE (Return on Equity) of Astellas Pharma this year?
The ROE of Astellas Pharma this year is 0.01 undefined.
In 2024, Astellas Pharma's return on equity (ROE) was 0.01, a -87.43% increase from the 0.08 ROE in the previous year.
Astellas Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Analyzing Astellas Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Astellas Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Changes in Astellas Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
The ROE of Astellas Pharma this year is 0.01 undefined.
The ROE of Astellas Pharma has increased by -87.43% decreased compared to the previous year.
A high ROE indicates that Astellas Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
A low ROE can indicate that Astellas Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.
A change in ROE (Return on Equity) of Astellas Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Some factors that can influence Astellas Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.37 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.
The current dividend yield of Astellas Pharma is 4.37 %.
Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.
Astellas Pharma paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.47 %.
Astellas Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.
The last dividend was paid out on 12/1/2024.
In the year 2023, Astellas Pharma distributed 65 JPY as dividends.
The dividends of Astellas Pharma are distributed in JPY.
The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank
Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.